LINCOLNSHIRE, Ill.– Nexus Pharmaceuticals, Inc., a U.S.-based healthcare company and domestic pharmaceutical manufacturer, has received a patent covering applications of EMERPHED® Ready-To-Use Ephedrine Sulfate Injection, the first FDA-approved premixed ephedrine in a ready-to-use 50 mg/10 mL vial. The United States Patent and Trademark Office (USPTO) issued the patent, U.S. Patent No. 11,090,278, on August 17, 2021.
“We are very proud of the intellectual property that was created during the development of EMERPHED®,” said Shahid Ahmed, Chief Scientific Officer of Nexus Pharmaceuticals. “The granting of this patent is the culmination of many years of scientific development and the hard work of our dedicated team.”
In February 2021, the Medical College of Wisconsin published a clinical study showing the reduction of potential risk for error and ease of use of EMERPHED® as compared to commercially used concentrated ephedrine. MCW published a press release with their findings in February 2021, and the clinical study was published in the Journal of Pharmaceutical Science and Technology in June 2021.
Ephedrine Sulfate injection is an alpha- and beta-adrenergic agonist and a norepinephrine-releasing agent that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia.
